Bart Kus
University of Toronto
7 Papers
117 Citations
Bart Kus is an academic researcher from University of Toronto. The author has contributed to research in topics: Ubiquitin ligase & Ubiquitin-conjugating enzyme. The author has an hindex of 7, co-authored 7 publications.
Chat about Author
Papers
Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast.
Ronish Gupta,Bart Kus,Christopher Fladd,James D. Wasmuth,Raffi Tonikian,Sachdev S. Sidhu,Nevan J. Krogan,John Parkinson,Daniela Rotin +8 more
TL;DR: The development of a novel proteomic in vitro ubiquitination screen using a protein microarray platform that can be utilized for the discovery of substrates for E3 ligases on a global scale is described.
181
The mRNA Nuclear Export Factor Hpr1 Is Regulated by Rsp5-mediated Ubiquitylation *
Carole Gwizdek,Maria Hobeika,Bart Kus,Batool Ossareh-Nazari,Catherine Dargemont,Manuel S. Rodriguez +5 more
TL;DR: Hpr1p is identified, a member of the THO/TREX (transcription/export) complex that couples mRNA transcription to nuclear export as a target of the ubiquitin-proteasome pathway, and represents the first nuclear export factor regulated by ubiquitylation.
79
Functional interaction of 13 yeast SCF complexes with a set of yeast E2 enzymes in vitro.
TL;DR: It is found that the ubiquitination of Sic1 by the reconstituted SCFCdc4 complex was specifically catalyzed by two of the five E2 enzymes tested in vitro; Cdc34 and Ubc4.
74
A High Throughput Screen to Identify Substrates for the Ubiquitin Ligase Rsp5
Bart Kus,Aaron Gajadhar,Karen Stanger,Rob Cho,Warren Sun,Nathalie Rouleau,Tammy K. Lee,Donovan Chan,Cheryl Wolting,Aled M. Edwards,Roger Bosse,Daniela Rotin +11 more
TL;DR: A luminescent assay to detect ubiquitination in vitro, which is more quantitative, effective, and sensitive than conventional ubiquitinated assays, and the combination of this sensitive assay and the availability of purified substrates will enable the identification of substrates for any purified E3 enzyme.
48
Ibuprofen rescues mutant cystic fibrosis transmembrane conductance regulator trafficking.
Graeme W. Carlile,Renaud Robert,Julie Goepp,Elizabeth Matthes,Jie Liao,Bart Kus,Sean Dale MacKnight,Daniela Rotin,John W. Hanrahan,David Y. Thomas +9 more
TL;DR: These studies show that ibuprofen is a CFTR corrector and that it causes correction by COX-1 inhibition and may be suitable to be part of a future CF combination therapy.